Development of novel, safe and effective drug candidates combating the emerging drug resistance has remained a major focus in the mainstream of anti-tuberculosis research. Here, we inspired to design and synthesize series of new pyridin-4-yl-1,3,4-oxadiazol-2-yl-thio-ethylidene-hydrazinecarbothioamide derivatives as potential anti-tubercular agents. The anti-tubercular bioactive assay demonstrated that the synthesized compounds exhibit potent anti-tubercular activity (MIC = 3.9-7.81 μg/mL) in comparison with reference drugs Rifampicin and Isoniazid.We employed pharmacophore probing approach for the identification of CYP51 as a possible drug target for the synthesized compounds. To understand the preferable binding mode, the synthesized molecules were docked onto the active site of Sterol 14 α-demethylases (CYP51) target. From the binding free energy of the docking results it was revealed that the compounds were effective CYP51 inhibitors and acts as antitubercular agent.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.compbiolchem.2019.03.002DOI Listing

Publication Analysis

Top Keywords

potent anti-tubercular
8
synthesized compounds
8
design synthesis
4
synthesis silico
4
silico study
4
study pyridine
4
pyridine based
4
based 134-oxadiazole
4
134-oxadiazole embedded
4
embedded hydrazinecarbothioamide
4

Similar Publications

Exploration of triazole derivatives, SAR profiles, and clinical pipeline against Mycobacterium tuberculosis.

Bioorg Chem

December 2024

Medicinal Chemistry Research Laboratory, School of Pharmaceutical Sciences, Siksha O Anusandhan Deemed to be University, Bhubaneswar, Odisha 751003, India. Electronic address:

Tuberculosis is a highly infectious disease and it is a global threat in particular affecting people from developing countries. It is thought that nearly one-third of the global population lives with this causative bacterium in its dominant form. The spread of HIV and the development of resistance to both multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) aggravates the spread of the disease and needs novel drugs which combat this disease effectively.

View Article and Find Full Text PDF

In this study, we designed, synthesized and evaluated some novel imidazo[1,2-]pyridine derivatives as potential anti-TB agents. Preliminary screening for anti-TB activity of the synthesized compounds was performed against H37Rv strain using the microplate Alamar Blue assay (MABA). Network pharmacology was used to identify the possible targets and pathways of these compounds against Mtb infection.

View Article and Find Full Text PDF

In silico studies on nicotinamide analogs as competitive inhibitors of nicotinamidase in methicillin-resistant Staphylococcus aureus.

Mol Divers

November 2024

Structural Biology & Bioinformatics Laboratory, Department of Biosciences, Manipal University Jaipur, Jaipur-Ajmer Express Highway, Jaipur, Rajasthan, 303007, India.

Nicotinamidase/PncA is a member of the hydrolase enzyme family, catalyzing the de-amidation of nicotinamide (NM) to nicotinic acid (NA) via salvage pathway. Products are fed into Preiss-Handler pathway for NAD biosynthesis which is an important enzyme cofactor and crucial for redox balance in microorganisms. Pathogens like methicillin-resistant Staphylococcus aureus (MRSA) are NAD auxotroph and rely on their host environment for NAD precursors to synthesize NAD.

View Article and Find Full Text PDF

Arenicolide Family Macrolides Provide a New Therapeutic Lead Combating Multidrug-Resistant Tuberculosis.

Angew Chem Int Ed Engl

January 2025

Natural Products Research Institute, College of Pharmacy, Seoul National University, 1 Gwanak-ro, Gwanak-gu, 08826, Seoul, Republic of Korea.

Article Synopsis
  • - The study highlights the urgent issue of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Mycobacterium tuberculosis (Mtb), which poses a global health threat.
  • - Researchers discovered eight new compounds called arenicolides from a bacterium found in the gut of black oil beetles, including arenicolide A (Ar-A), which exhibits strong antimicrobial activity against MDR and XDR strains of Mtb.
  • - Ar-A effectively weakens the Mtb cell wall and depletes ATP, showing significant potential as a treatment for drug-resistant tuberculosis, especially when combined with the antibiotic amikacin in mice.
View Article and Find Full Text PDF

Design, synthesis, biological evaluation study of spirocyclic POM analogues as novel MmpL3 anti-tubercular agent.

Bioorg Chem

December 2024

Medicinal Chemistry, Institut Pasteur Korea, Seongnam-si 13488, Korea. Electronic address:

We present the development of a phenyl oxazole methyl (POM) core structure with spirocyclic derivatives as part of our efforts to discover innovative anti-tuberculosis agents. Derivatives of spirocyclic POM were synthesized and evaluated for their inhibitory effects on M.tuberculosis (M.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!